×

Summit shares drop after US FDA declines to approve lung cancer drug

By Thomson Reuters Nov 16, 2026 | 5:29 AM

Nov 16 (Reuters) – Shares of Summit Therapeutics fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration declined to approve its experimental lung ​cancer drug ivonescimab.

The regulator on Sunday cited the drug’s ‌failure to achieve statistical significance in overall survival, a key measure of long-term treatment benefit, in a late-stage study that formed part of Summit’s marketing application.

The decision establishes a “meaningful regulatory precedent” for the drug class, with potential ‌implications ​for similar drug candidates being developed by ⁠Bristol-Myers Squibb, BioNTech, Pfizer, ⁠Merck and AbbVie, said BMO Capital analyst Evan Seigerman.

Ivonescimab is designed to block two proteins: PD-1, which helps cancer evade the immune system, and VEGF, which tumors use to grow ​blood vessels.

Summit’s shares were down 19.9% at $11.33 before the bell.

The company had sought approval for ivonescimab, in combination with chemotherapy, ⁠for previously treated patients with advanced ⁠non-squamous non-small cell lung cancer (NSCLC) carrying EGFR genetic mutations.

The ​condition is the most common type of lung cancer, with the ​EGFR mutation occuring in 10% to 15% of cases ‌in the US, according to the American Lung Association.

The FDA’s decision was consistent with the high bar the agency had previously set, TD Cowen analysts said after the move.

Analysts are now closely ⁠watching data from a separate late-stage study expected later this year, in which the drug in combination with chemotherapy was tested as a ⁠first-line treatment for ‌patients with NSCLC.

The FDA’s rejection on Sunday does ⁠not impact the probability of success for ivonescimab ​in ‌first-line NSCLC, “which remains the substantially larger and more ​important commercial ⁠opportunity,” TD Cowen analysts said.

Summit acquired rights to the drug in the US, Canada, Europe and Japan from China’s Akeso in 2022 under a deal valued at up to $5 billion. Akeso retained rights in China and other markets.

(Reporting by Mariam Sunny in Bengaluru; Editing ​by Jonathan Ananda)